 |
|
| On September 27, 2018, Cellular Biomedicine Group Inc. (NASDAQ: CBMG) announced it entered into a strategic licensing and collaboration agreement with Novartis to manufacture and supply the CAR-T cell therapy Kymriah® in China. |
|
|
|
|
| |
Dr. Joanne Kurtzberg, medical director of the Carolinas Cord Blood Bank and Marcus Center for Cellular Cures, will present the latest data on autologous cord blood infusions in children with hypoxic ischemic encephalopathy, cerebral palsy, congenital hydrocephalus and autism, and adults with acute ischemic stroke. This event is on October 15 at AABB. Admission is free but you do have to register. |
|
|
|
|
| |
| Pompano Beach, FL, Oct. 01, 2018 — BioStem Life Sciences, a wholly owned subsidiary of BioStem Technologies, Inc. (OTC PINK: BSEM), has entered the market with four placental-derived tissue products for multiple indications within the ophthalmology, orthopedic and advanced wound care markets. |
|
|
|
|
| |
| Major news broke in the iPSC sector when Ncardia and Nanion Technologies signed a joint marketing and sales promotion agreement. Customers of the companies will get access to high-performance instrument platforms from Nanion, coupled with Ncardia’s portfolio of hiPSC-derived cardiac cell types and assay services. |
|
|
|
|
|
In recent months, exosome start-up companies have been the recipients of approximately $386.2 million in investor funding. Do you know the identities of the four most richly funded exosome startups in the world today? |
|
|
|
|
| |
SAN DIEGO, Sept. 17, 2018 — Fate Therapeutics has entered into a collaboration with ONO Pharmaceutical for joint development of two off-the-shelf CAR-T cell product candidates. Fate Therapeutics and ONO will jointly advance each iPSC-derived CAR-T cell collaboration candidate to a pre-defined preclinical milestone. |
|
|
|
|
| |
Are you familiar with AI and blockchain? As a stakeholder in healthcare, if you’re not you soon will be, according to Dr. Kala Fleming, an innovation leader at IBM. Fleming is a featured speaker at the HEALinc Future Health Innovation Summit, which will be held on October 7-9 in Nassau, Bahamas. |
|
|
|
|
| |
SEOUL, South Korea, Sept. 12, 2018 — ExoCoBio Inc. has raised about $27 million in its Series B funding. Since it was established in January 2017, ExoCoBio has raised $46 million accumulatively, including a Series A round in April 2017 of $11 million. |
|
|
|
|
|
Anyone who has watched a friend or loved one succumb to the slow degradation of Parkinson’s disease will understand the urge to cure it. Thankfully, researchers in Japan are exploring a treatment involving the use iPS cells to create dopaminergic progenitors to be injected in the brains of seven human patients. |
|
|
|
|
| |
Stem cell therapy in India is emerging as a new modality within the healthcare system. The progress is supported by numerous innovators within the country. One company forging the way is ReeLabs, a leading stem cell bank in India that is also developing novel stem cell therapeutics. |
|
|
|
|
| |
What are stem cells used for? There are many potential uses for stem cells, from the treatment of cancer to chronic conditions, acute injuries and more. Scientists continue to perform research on stem cells to maximize their therapeutic benefits and possible contributions to the medical industry. |
|
|
|
|
|
Who discovered stem cells is a question worthy of exploration. For several hundred years, researchers have known that the human body is comprised of trillions of tiny structures.This articles explores the researchers and physicians who created the emerging field of stem cell medicine. |
|
|
|
|
|
In this 21-page, 50+ respondent survey, cell therapy manufacturing executives reveal when and why they choose to partner with a contact manufacturing organization (CMO). It reveals the selection criteria that cell therapy executives use, as well as their perspectives on manufacturing capacity, geography, pure-play versus hybrid CMOs, and much more. |
|
|
|
|
|
Benefits of partnering with a cell or gene therapy contract manufacturing organization (CMO) include scalability, speed to market, access to technical expertise, and cost efficiencies. This searchable, sortable database aggregates cell and gene therapy CMOs / CDMOs to provide you with a complete list of potential manufacturing partners. |
|
|
|
|
| |
The regenerative medicine (RM) industry is rapidly expanding, driven by a high volume of clinical trials, accelerated pathways for product approvals, and the potential for regenerative medicine therapies to revolutionize healthcare. For a limited-time, you can reveal the identities of 650+ regenerative medicine companies worldwide for only $97 (50% off). |
|
|
|
|
